C4 Therapeutics, Inc.
CCCC
$4.26
-$0.14-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -44.15% | -1.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -44.15% | -1.91% | |||
| Cost of Revenue | 101.65% | -370.43% | |||
| Gross Profit | -93.86% | 650.83% | |||
| SG&A Expenses | 1.66% | 2.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.66% | -2.14% | |||
| Operating Income | -20.05% | 2.26% | |||
| Income Before Tax | -23.39% | 36.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.66% | 36.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.66% | 36.31% | |||
| EBIT | -20.05% | 2.26% | |||
| EBITDA | -20.53% | 2.16% | |||
| EPS Basic | -13.63% | 60.43% | |||
| Normalized Basic EPS | -9.68% | 38.46% | |||
| EPS Diluted | -13.63% | 60.43% | |||
| Normalized Diluted EPS | -9.68% | 38.46% | |||
| Average Basic Shares Outstanding | 7.96% | 60.94% | |||
| Average Diluted Shares Outstanding | 7.96% | 60.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||